Deutsche Bank
ZNTL icon

Deutsche Bank’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Deutsche Bank’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
+48,806
New +$195K ﹤0.01% 3161
2025
Q2 		– Sell
-42,804
Closed -$68.1K – 3758
2025
Q1 		$68.1K Hold
42,804
– – ﹤0.01% 3313
2024
Q4 		$130K Buy
42,804
+10,873
+34% +$35.6K ﹤0.01% 3223
2024
Q3 		$118K Buy
31,931
+8,184
+34% +$29.7K ﹤0.01% 3159
2024
Q2 		$97.1K Sell
23,747
-7,078
-23% -$79K ﹤0.01% 3118
2024
Q1 		$486K Sell
30,825
-12,081
-28% -$166K ﹤0.01% 2365
2023
Q4 		$650K Buy
42,906
+10,826
+34% +$158K ﹤0.01% 2240
2023
Q3 		$644K Sell
32,080
-387,146
-92% -$9.83M ﹤0.01% 2002
2023
Q2 		$11.8M Buy
419,226
+374,402
+835% +$8.98M 0.01% 927
2023
Q1 		$771K Buy
44,824
+7,428
+20% +$150K ﹤0.01% 2255
2022
Q4 		$753K Sell
37,396
-31,258
-46% -$672K ﹤0.01% 2225
2022
Q3 		$1.49M Buy
68,654
+46,126
+205% +$1.26M ﹤0.01% 1748
2022
Q2 		$633K Sell
22,528
-10,624
-32% -$281K ﹤0.01% 2452
2022
Q1 		$1.53M Sell
33,152
-1,834
-5% -$98.9K ﹤0.01% 2054
2021
Q4 		$2.94M Buy
34,986
+1,183
+3% +$91.5K ﹤0.01% 1756
2021
Q3 		$2.25M Buy
33,803
+11,438
+51% +$660K ﹤0.01% 2006
2021
Q2 		$1.19M Buy
22,365
+831
+4% +$44.5K ﹤0.01% 2666
2021
Q1 		$934K Sell
21,534
-1,843
-8% -$79.3K ﹤0.01% 2709
2020
Q4 		$1.21M Buy
23,377
+17,122
+274% +$772K ﹤0.01% 2316
2020
Q3 		$205K Buy
6,255
+1,019
+19% +$35.7K ﹤0.01% 3201
2020
Q2 		$252K Buy
+5,236
New +$201K ﹤0.01% 3026

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deutsche Bank's ZNTL Position: Q2 2026 in Review

Deutsche Bank opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 48,806 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #3161 among its holdings. This is a return to the name: Deutsche Bank previously reported a position in ZNTL as recently as Q1 2025.

Deutsche Bank first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $11.8M in Q2 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Deutsche Bank held 48,806 shares of Zentalis Pharmaceuticals worth $237K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Deutsche Bank position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3161 holding.
  • Deutsche Bank first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Deutsche Bank's Zentalis Pharmaceuticals position peaked at $11.8M in Q2 2023.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.